AAPL 242.195 -3.2845% MSFT 415.4 -1.4472% NVDA 136.11 1.3553% GOOGL 188.45 -0.449% GOOG 189.67 -0.4043% AMZN 218.77 -0.2826% META 592.1525 1.1345% AVGO 230.54 -0.5607% TSLA 377.02 -6.6412% TSM 199.64 1.0887% LLY 774.59 0.3355% V 312.71 -1.0537% JPM 239.57 -0.0584% UNH 504.27 -0.3143% NVO 87.56 1.7903% WMT 89.7 -0.7194% LVMUY 128.99 -1.3008% XOM 107.02 -0.5113% LVMHF 645.0 -1.7816% MA 518.315 -1.5677%
Last update at 2025-01-02T18:56:00Z
BRKR Stock to Gain From Newly Formed Bruker Spatial Biology Division
Thu 17 Oct 24, 02:58 PMIs Bruker Corporation (BRKR) the Most Profitable Mid-Cap Stock to Invest In Now?
Thu 17 Oct 24, 04:08 AMUS Growth Stocks With High Insider Ownership In October 2024
Wed 09 Oct 24, 07:31 PMBRKR Stock Might Gain From the Newly Launched OptoVolt Module
Wed 09 Oct 24, 12:44 PMBruker Corporation (NASDAQ:BRKR) Delivered A Better ROE Than Its Industry
Tue 08 Oct 24, 12:25 PMBruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors
Mon 07 Oct 24, 06:06 PMHere's Why You Should Retain BRKR Stock in Your Portfolio Now
Thu 03 Oct 24, 12:20 PMAccelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
Tue 01 Oct 24, 04:12 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 413.90M | 393.60M | 225.80M | 280.40M | 244.70M |
| Minority interest | -1.90000M | -3.50000M | 7.60M | 0.80M | 1.30M |
| Net income | 296.60M | 277.10M | 157.80M | 197.20M | 179.70M |
| Selling general administrative | 610.80M | 564.50M | 477.80M | 500.20M | 444.70M |
| Selling and marketing expenses | -3.40000M | -3.30000M | -9.20000M | - | - |
| Gross profit | 1305.70M | 1209.60M | 939.80M | 995.30M | 900.00M |
| Reconciled depreciation | 88.00M | 89.10M | 80.40M | 75.60M | 64.90M |
| Ebit | 432.70M | 413.30M | 248.30M | 300.90M | 281.90M |
| Ebitda | 550.40M | 516.70M | 353.60M | 383.00M | 346.80M |
| Depreciation and amortization | 117.70M | 103.40M | 105.30M | 82.10M | 64.90M |
| Non operating income net other | -18.80000M | -19.70000M | -22.50000M | -20.50000M | -17.70000M |
| Operating income | 432.70M | 413.30M | 248.30M | 300.90M | 262.40M |
| Other operating expenses | 2068.30M | 1990.30M | 1714.30M | 1765.20M | 1613.70M |
| Interest expense | 16.10M | 14.30M | 14.40M | 16.00M | 12.60M |
| Tax provision | 116.40M | 113.00M | 64.40M | 82.40M | 63.70M |
| Interest income | 4.10M | 0.90M | 3.20M | 1.30M | 1.20M |
| Net interest income | -18.80000M | -19.70000M | -22.50000M | -14.70000M | -11.40000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 116.40M | 113.00M | 64.40M | 82.40M | 63.70M |
| Total revenue | 2530.70M | 2417.90M | 1987.50M | 2072.60M | 1895.60M |
| Total operating expenses | 843.30M | 782.00M | 666.60M | 687.90M | 618.10M |
| Cost of revenue | 1225.00M | 1208.30M | 1047.70M | 1077.30M | 995.60M |
| Total other income expense net | -18.80000M | -19.70000M | -22.50000M | -20.50000M | -19.50000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 298.50M | 280.60M | 168.90M | 198.00M | 181.00M |
| Net income applicable to common shares | 296.60M | 277.10M | 157.80M | 197.20M | 179.70M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 4249.90M | 3618.50M | 3650.00M | 3047.90M | 2771.50M |
| Intangible assets | 330.50M | 270.90M | 211.80M | 229.10M | 603.50M |
| Earning assets | - | - | - | - | - |
| Other current assets | 85.80M | 202.60M | 176.60M | 165.50M | 172.00M |
| Total liab | 2836.60M | 2486.70M | 2565.20M | 2072.30M | 1854.40M |
| Total stockholder equity | 1377.20M | 1125.70M | 1084.60M | 975.60M | 917.10M |
| Deferred long term liab | - | 62.30M | 46.00M | 43.10M | 48.80M |
| Other current liab | 454.90M | 487.10M | 481.20M | 467.60M | 388.80M |
| Common stock | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M |
| Capital stock | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M |
| Retained earnings | 2323.80M | 1926.00M | 1659.50M | 1406.50M | 1274.70M |
| Other liab | - | 318.20M | 404.90M | 389.40M | 311.00M |
| Good will | 582.60M | 457.60M | 339.50M | 320.40M | 293.00M |
| Other assets | - | 208.90M | 160.90M | 180.00M | 77.30M |
| Cash | 488.30M | 645.50M | 1068.20M | 681.80M | 678.30M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1202.10M | 913.80M | 938.50M | 793.60M | 645.60M |
| Current deferred revenue | 400.00M | 225.70M | 197.50M | 189.20M | 137.90M |
| Net debt | 891.30M | 573.70M | 266.00M | 209.70M | 182.00M |
| Short term debt | 144.50M | 18.70M | 112.40M | 2.20M | 0.50M |
| Short long term debt | 121.20M | 18.70M | 112.40M | 2.20M | 0.50M |
| Short long term debt total | 1379.60M | 1219.20M | 1334.20M | 891.50M | 860.30M |
| Other stockholder equity | -954.30000M | -816.80000M | -568.40000M | -436.30000M | -333.80000M |
| Property plant equipment | - | 487.00M | 406.10M | 395.50M | 306.10M |
| Total current assets | 2164.20M | 2124.50M | 2471.80M | 1924.90M | 1796.30M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 1210.90M | 312.50M | 509.60M | 491.50M |
| Short term investments | 12.00M | 100.00M | 100.00M | 50.00M | 6.60M |
| Net receivables | 621.80M | 472.70M | 416.90M | 335.30M | 362.20M |
| Long term debt | 1160.30M | 1200.50M | 1221.80M | 842.30M | 812.80M |
| Inventory | 968.30M | 803.70M | 710.10M | 692.30M | 577.20M |
| Accounts payable | 202.70M | 182.30M | 147.40M | 134.60M | 118.40M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 11.90M | 14.10M | 13.10M | 10.30M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 6.00M | 14.80M | -8.20000M | 3.70M | -25.50000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 1.70M | 1.70M | 1.70M | 1.70M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 1926.00M | 1659.50M | 1406.50M | 1274.70M |
| Treasury stock | - | -1085.00000M | -820.30000M | -667.00000M | -543.80000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 175.70M | -76.80000M | 70.80M | 39.60M | 16.80M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 2085.70M | 1494.00M | 1178.20M | 1123.00M | 975.20M |
| Capital lease obligations | 98.10M | 51.20M | 59.70M | 47.00M | 67.60M |
| Long term debt total | - | 1200.50M | 1221.80M | 842.30M | 812.80M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -438.50000M | -239.30000M | -50.30000M | -36.50000M | -6.40000M |
| Change to liabilities | - | 30.80M | 100.60M | 57.40M | 29.00M |
| Total cashflows from investing activities | - | -251.60000M | -192.40000M | -192.70000M | -158.40000M |
| Net borrowings | - | 0.30M | 489.60M | -8.40000M | 462.60M |
| Total cash from financing activities | -193.40000M | -415.20000M | 318.70M | -161.60000M | 300.00M |
| Change to operating activities | - | 2.60M | -19.20000M | 11.00M | -49.80000M |
| Net income | 427.20M | 298.50M | 280.60M | 161.40M | 198.00M |
| Change in cash | -157.20000M | -423.00000M | 386.20M | 3.60M | 355.60M |
| Begin period cash flow | 645.50M | 1071.70M | 685.50M | 681.90M | 326.30M |
| End period cash flow | 488.30M | 648.70M | 1071.70M | 685.50M | 681.90M |
| Total cash from operating activities | 350.10M | 262.00M | 282.40M | 333.20M | 213.40M |
| Issuance of capital stock | 6.80M | 2.80M | 7.00M | 3.30M | 10.90M |
| Depreciation | 114.90M | 88.00M | 89.10M | 80.40M | 75.60M |
| Other cashflows from investing activities | - | -168.40000M | 10.00M | -59.00000M | -79.00000M |
| Dividends paid | 29.40M | 29.80M | 24.20M | 24.60M | 25.00M |
| Change to inventory | -125.00000M | -140.10000M | -67.00000M | -87.90000M | -60.20000M |
| Change to account receivables | -0.90000M | -67.90000M | -95.30000M | 40.80M | -5.00000M |
| Sale purchase of stock | -152.30000M | -263.10000M | -153.30000M | -123.20000M | -142.30000M |
| Other cashflows from financing activities | 0.30M | -14.10000M | 492.40M | 288.70M | 837.90M |
| Change to netincome | - | 12.90M | 41.40M | -6.50000M | 4.20M |
| Capital expenditures | 106.90M | 119.00M | 92.00M | 98.20M | 73.00M |
| Change receivables | - | -67.90000M | -95.30000M | 40.80M | -5.00000M |
| Cash flows other operating | - | 49.20M | 26.20M | 90.30M | -28.20000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -392.50000M | 408.70M | -22.10000M | 355.00M |
| Change in working capital | -87.80000M | -143.50000M | -125.20000M | 76.00M | -74.50000M |
| Stock based compensation | 24.00M | 27.70M | 17.20M | 16.00M | 9.60M |
| Other non cash items | -103.80000M | 8.10M | 26.50M | 24.80M | 10.10M |
| Free cash flow | 243.20M | 143.00M | 190.40M | 235.00M | 140.40M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BRKR Bruker Corporation |
0.49 0.84% | 59.11 | 28.31 | 31.95 | 4.07 | 8.75 | 4.37 | 19.16 |
| ABT Abbott Laboratories |
-0.27 0.24% | 112.84 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-2.75 0.76% | 357.30 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.01 0.01% | 79.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.41 0.46% | 88.91 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
40 Manning Road, Billerica, MA, United States, 01821
| Name | Title | Year Born |
|---|---|---|
| Dr. Frank H. Laukien Ph.D. | Chairman, CEO & Pres | 1960 |
| Mr. Gerald N. Herman | Exec. VP & CFO | 1958 |
| Dr. Mark R. Munch Ph.D. | Corp. Exec. VP and Pres of Bruker Nano Group & Corp. | 1962 |
| Mr. Juergen Srega | Pres of Bruker CALID Group & Bruker Daltonics Division | 1955 |
| Dr. Falko Busse Ph.D. | Pres of Bruker BioSpin Group | 1967 |
| Mr. Justin Joseph Ward | Sr. Director of Investor Relations & Corp. Devel. | NA |
| Mr. J. Brent Alldredge J.D. | Gen. Counsel | 1975 |
| Mr. Collin J. D'Silva | Pres of Chemical Analysis Division | 1957 |
| Stacey Desrochers | Treasurer & Director of Investor Relations | NA |
| Mr. Urban Faeh | Pres of Bruker Optics Division & Managing Director of Bruker Optik GmbH | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...